IMV’s corporate headquarters are located at:

United States

United States of America
10 Rogers Street
Suite 120 and 121
Cambridge, MA 02142-1288
T: +1 (617)-294-5868


2875 Boulevard Laurier
Delta 1, Suite 220
Québec, Québec City, G1V2M2
T: +1 (581) 741-0519

Headquarters / Nova Scotia

130 Eileen Stubbs Avenue, Suite 19
Dartmouth, Nova Scotia, B3B 2C4
T: +1 (902) 492-1819
F: +1 (902) 492-0888

The Company was founded on March 28, 2000, under the name Immunovaccine Technologies Inc. (IVT.)

IMV Inc. started trading on the TSX-Venture Exchange in Canada on October 5, 2009, under the ticker symbol “IMV”. The Company graduated to the Toronto Stock Exchange on November 26, 2014.

On June 1st, 2018, the company joined the Nasdaq exchange under the ticker IMV.

44974L103 and CA44974L1031

Click here for Investor Relations inquiries.

PricewaterhouseCoopers LLP (PWC)
Place de la Cité, Tour Cominar, 2640, boulevard Laurier, bureau 1700, Québec QC G1V 5C2

McCarthy Tétrault LLP

Troutman Sanders

Computershare Investor Services Inc.
100 University Avenue, 8th Floor
Toronto, Ontario M5J 2Y1
1-800-564-6253 (North America) or 514-982-7555 from all other countries

Please mention IMV’s CUSIP number, 44974L103 in all correspondence with Computershare.

The Company's fiscal year end date is December 31.

Click here to see the analysts that follow IMV Inc.

Click here to see the IMV Inc. Board of Directors.

Electronic copies of our SEC and SEDAR filings are available in the Investors section of this website as well as on SEDAR and EDGAR.

Shareholders approved the corporate name change in May 2018 to better reflect the business of the Company, which is more than vaccines.